EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis

Lourdes Encinas, Si-Yang Li, Joaquin Rullas-Trincado, Rokeya Tasneen, Sandeep Tyagi, Heena Soni, Adolfo Garcia-Perez, Jin Lee, Rubén González Del Río, Jaime De Mercado, Verónica Sousa, Izidor Sosič und 7 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00357-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Lourdes Encinas und 18 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Isoniazid, Bacterial Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isoniazid is an important first-line medicine to treat tuberculosis (TB). Isoniazid resistance increases the risk of poor treatment outcomes and development of multidrug resistance, and is driven primarily by mutations involving katG , encoding the prodrug-activating enzyme, rather than its validated target, InhA. The chemical tractability of InhA has fostered efforts to discover direct inhibitors of InhA (DIIs). In this study, we bridge the gap in understanding the potential contribution of DIIs to novel combination regimens and demonstrate a clear distinction of DIIs, like GSK693 and the newly described GSK138, from isoniazid, based on activity against clinical isolates and contribution to novel drug regimens. The results suggest that DIIs, specifically GSK138 and GSK693, could be promising partners in novel drug regimens, including those used against isoniazid-resistant TB, potentially enhancing their efficacy and/or preventing the selection of resistant mutants and supporting the continued exploration of InhA as a promising target for TB drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsMycobacterium tuberculosisIsoniazidBacterial ProteinsOxidoreductasesDisease Models, AnimalAnimalsMiceTuberculosis, Multidrug-ResistantMicrobial Sensitivity TestsTuberculosisFemale

Stichwörter der Autor:innen

GSK138GSK2505693AGSK3081138AGSK693InhA inhibitormousetuberculosistuberculosis drugs

Substanzen

Antitubercular AgentsInhA protein, MycobacteriumIsoniazidBacterial ProteinsOxidoreductases

Autor:innen und Institutionen

  • Global Health Medicines R&D, GSK, Tres Cantos, Madrid, Spain.
  • Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
  • Discovery DMPK, GSK, Tres Cantos, Madrid, Spain.
  • Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.
  • TB Alliance: Global Alliance for Tuberculosis Drug Development, New York, New York, USA.

ORCID-Profile: Paul J Converse, David Barros-Aguirre, Eric L Nuermberger

Zitieren

APA

Encinas, L., Li, S. Y., Rullas-Trincado, J., Tasneen, R., Tyagi, S., Soni, H., Garcia-Perez, A., Lee, J., González Del Río, R., De Mercado, J., Sousa, V., Sosič, I., Gobec, S., Mendoza-Losana, A., Converse, P. J., Mdluli, K., Fotouhi, N., Barros-Aguirre, D., & Nuermberger, E. L. (2024). Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00357-24

Vancouver

Encinas L, Li SY, Rullas-Trincado J, Tasneen R, Tyagi S, Soni H, et al. Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00357-24

BibTeX
@article{Encinas2024,
  author = {Encinas, Lourdes and Li, Si-Yang and Rullas-Trincado, Joaquin and Tasneen, Rokeya and Tyagi, Sandeep and Soni, Heena and Garcia-Perez, Adolfo and Lee, Jin and González Del Río, Rubén and De Mercado, Jaime and Sousa, Verónica and Sosič, Izidor and Gobec, Stanislav and Mendoza-Losana, Alfonso and Converse, Paul J and Mdluli, Khisi and Fotouhi, Nader and Barros-Aguirre, David and Nuermberger, Eric L},
  title = {Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00357-24}
}
Kostenlos starten →